# Postpartum women’s prospective acceptability of long-acting HIV prevention approaches in Kenya: A qualitative study

**Authors:** Tessa Concepcion, John Kinuthia, Felix A Otieno, Eunita Akim, Helen Aketch, Laurén Gómez, Grace John-Stewart, Bih Moki Suh, Emmaculate M Nzove, Nancy Ngumbau, Jerusha N Mogaka, Sarah Obatsa, Ben O Odhiambo, Caroline Omom, Marin Strong, Anjuli D Wagner, Salphine Watoyi, Jillian Pintye

PMC · DOI: 10.21203/rs.3.rs-6058755/v1 · Research Square · 2025-02-27

## TL;DR

Postpartum women in Kenya prefer long-acting HIV prevention methods like injectables over daily pills due to convenience and fewer side effects.

## Contribution

This study explores the acceptability of long-acting HIV prevention among postpartum women in Kenya, identifying preferences and barriers specific to this population.

## Key findings

- Most postpartum women expressed high interest in long-acting PrEP due to reduced pill burden and side effects.
- Concerns about injectable safety during pregnancy and vaginal ring use during delivery were raised.
- Participants emphasized the need for education on safety and adherence strategies like mobile reminders.

## Abstract

New long-acting pre-exposure prophylaxis (LA-PrEP) options offer an alternative to daily oral PrEP, which poses difficulties for adherence, especially during pregnancy and postpartum. Yet, limited data exist on LA-PrEP acceptability among pregnant and postpartum women. We aimed to evaluate its acceptability and identify strategies to enhance it.

We conducted an exploratory qualitative study with postpartum women in five public health facilities in Kisumu and Siaya Counties, Kenya. In-depth interviews (IDIs) were conducted with women expressing high, low, and mixed LA-PrEP interest throughout pregnancy and postpartum. Inductive and deductive content analysis was used, and themes of acceptability were explored using the Theoretical Framework of Acceptability (TFA).

We conducted 70 IDIs with postpartum women between August 2023 and March 2024. The majority (62.9%) expressed consistently high interest in LA-PrEP. Most viewed LA-PrEP, especially every two-month injectables, as highly acceptable due to reduced pill burden, side effects, and dosing frequency. Concerns were raised regarding injectable PrEP safety for the baby during pregnancy and suitability of using the vaginal ring during delivery. Participants emphasized the importance of education on the safety of these methods during pregnancy and breastfeeding, and strategies for improving adherence, such as mobile reminders. Overall, women preferred LA-PrEP options over daily oral PrEP for convenience, effectiveness, and privacy, with healthcare provider education seen as crucial.

We found high acceptability of LA-PrEP options among postpartum women with experience taking PrEP during pregnancy. The findings reveal diverse preferences and key factors influencing acceptability, including safety, discretion, and convenience.

## Full-text entities

- **Chemicals:** PrEP (-), LA (MESH:D007811)
- **Species:** Human immunodeficiency virus 1 (no rank) [taxon 11676], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11888558/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11888558/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC11888558/full.md

---
Source: https://tomesphere.com/paper/PMC11888558